Roche Hldg Ltd Spons (RHHBY) 36.5100 $RHHBY
Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results
Sean Williams, The Motley Fool - Motley Fool - 1 hr 7 mins ago
"I was wrong." Next to "Yes, I'll do the dishes" there may not be a rarer phrase to come out of my mouth. But, today it's the truth with Exelixis ' phase 3 COMET-1 trial involving cabozantinib (known commercially as Cometriq) going up in smoke. ...
Exelixis Drug Fails Pivotal Prostate Cancer Study
at The Street - 2 hrs 22 mins ago
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
INTERMUNE SHAREHOLDER ALERT - InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG
Business Wire - Wed Aug 27, 3:26PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG.
Seragon Pharmaceuticals Inc. Announces Closing of Its Acquisition by Genentech
GlobeNewswire - Wed Aug 27, 3:15PM CDT
Seragon Pharmaceuticals Inc., a leader in developing drugs for hormone dependent cancers, today announced the closing of its acquisition by Genentech, a member of the Roche Group, (SIX:RO) (SIX:ROG) (OTCQX:RHHBY). Deal terms included $725 million in cash up front along with $1.0 billion in contingent development milestone payments for total transaction value up to $1.725 billion. The acquisition includes Seragon's entire selective estrogen receptor degrader (SERD) program, including its most advanced compound, ARN-810, a next generation SERD that is currently being evaluated in a Phase I trial in postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+) breast cancer.
Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare
INVESTOR ALERT - InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG
Business Wire - Tue Aug 26, 5:58PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune" in connection with the sale of the Company to Roche Holding AG.
Roche Furthers Immunotherapy Program with SP142 Launch - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:22PM CDT
Roche (RHHBY) announced that Spring Bioscience, a member of the Roche Group, has launched its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody1.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Biotech ETFs Surge on InterMune-Roche Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Aug 26, 12:00PM CDT
The news of InterMune's acquisition by Roche has led to a rally in the biotech ETFs space.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG -- ITMN
PR Newswire - Tue Aug 26, 10:35AM CDT
Levi & Korsinsky is investigating the Board of Directors of InterMune, Inc. ("InterMune" or the "Company" (NASDAQ: ITMN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Roche Holding AG.
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.
Meet 5 Leading Stocks That Big Funds Are Buying
at Investor's Business Daily - Tue Aug 26, 7:02AM CDT
With the market in a confirmed uptrend, it's time to take a hard look at highly-rated stocks on the move. IBD's Screen Of The Day is Bolting RS Lines -- stocks such as BitAuto (BITA) -- whose stock price's relative strength is surging vs. the S&P 500...
Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...
SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of InterMune Inc. - ITMN
PR Newswire - Mon Aug 25, 4:46PM CDT
Pomerantz LLP is investigating claims on behalf of investors of InterMune Inc. ("InterMune" or the "Company" (NASDAQ: ITMN) (ISIN: US45884X1037) (CUSIP: 45884X103) concerning the proposed acquisition of InterMune by Roche Holding AG.
Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results
Sean Williams, The Motley Fool - Motley Fool - 1 hr 7 mins ago
"I was wrong." Next to "Yes, I'll do the dishes" there may not be a rarer phrase to come out of my mouth. But, today it's the truth with Exelixis ' phase 3 COMET-1 trial involving cabozantinib (known commercially as Cometriq) going up in smoke. ...
Exelixis Drug Fails Pivotal Prostate Cancer Study
at The Street - 2 hrs 22 mins ago
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery INTERMUNE SHAREHOLDER ALERT - InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG
Business Wire - Wed Aug 27, 3:26PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG. Seragon Pharmaceuticals Inc. Announces Closing of Its Acquisition by Genentech
GlobeNewswire - Wed Aug 27, 3:15PM CDT
Seragon Pharmaceuticals Inc., a leader in developing drugs for hormone dependent cancers, today announced the closing of its acquisition by Genentech, a member of the Roche Group, (SIX:RO) (SIX:ROG) (OTCQX:RHHBY). Deal terms included $725 million in cash up front along with $1.0 billion in contingent development milestone payments for total transaction value up to $1.725 billion. The acquisition includes Seragon's entire selective estrogen receptor degrader (SERD) program, including its most advanced compound, ARN-810, a next generation SERD that is currently being evaluated in a Phase I trial in postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+) breast cancer.
Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare
INVESTOR ALERT - InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG
Business Wire - Tue Aug 26, 5:58PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG. Roche Furthers Immunotherapy Program with SP142 Launch - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:22PM CDT
Roche (RHHBY) announced that Spring Bioscience, a member of the Roche Group, has launched its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody1.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Biotech ETFs Surge on InterMune-Roche Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Aug 26, 12:00PM CDT
The news of InterMune's acquisition by Roche has led to a rally in the biotech ETFs space.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG -- ITMN
PR Newswire - Tue Aug 26, 10:35AM CDT
Levi & Korsinsky is investigating the Board of Directors of InterMune, Inc. ("InterMune" or the "Company"
(NASDAQ: ITMN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Roche Holding AG. 3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.
Meet 5 Leading Stocks That Big Funds Are Buying
at Investor's Business Daily - Tue Aug 26, 7:02AM CDT
With the market in a confirmed uptrend, it's time to take a hard look at highly-rated stocks on the move. IBD's Screen Of The Day is Bolting RS Lines -- stocks such as BitAuto (BITA) -- whose stock price's relative strength is surging vs. the S&P 500...
Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...
SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of InterMune Inc. - ITMN
PR Newswire - Mon Aug 25, 4:46PM CDT
Pomerantz LLP is investigating claims on behalf of investors of InterMune Inc. ("InterMune" or the "Company"
(NASDAQ: ITMN) (ISIN: US45884X1037) (CUSIP: 45884X103) concerning the proposed acquisition of InterMune by Roche Holding AG. 
